Ark Biotech

Ark Biotech is a developer of AI-powered bioprocess simulation software for biopharma manufacturing. The company agentic bioprocess platform enables faster development and more robust manufacturing, trusted by top biopharma companies and CDMOs. The software allows users to run virtual bioreactor experiments in seconds, simulating thousands of experiments in parallel to optimize processes, ensure robustness, and scale up first time right. The platform tracks over 25 cell culture trends including growth metrics like titer, viability, and VCD, metabolic indicators like pCO2, lactate, and ammonia, plus soft sensors such as impeller and sparger P/V. Ark offers in-silico optimization that explores tens of thousands of process variations with a single click, ranking and comparing recipes to reveal optimal paths. The platform supports the full bioprocess lifecycle from pre-IND through commercial scale, works with sparse and imprecise data, is bioreactor-agnostic with customizable vessel geometry, and features a Bioprocess AI Assistant chatbot for interactive insights. Security includes SOC 2 Type II certification, AES-256 encryption, TLS 1.2-plus transit, single-tenant AWS hosting, and strict permission controls. Founded in 2021 and headquartered in Boston, United States, Ark Biotech has raised approximately 10.7 million at the Series A stage with investors including Primary Venture Partner, HCVC, and Hawktail.